How much funding has Artiva raised?

Artiva has raised $198.0M in total funding, most recently a Series B round.

Who are Artiva's investors?

Artiva's investors include 5AM Ventures, RA Capital Management, venBIO Partners, Venrock, GC LabCell Corporation, Green Cross Holdings Corporation.

Where is Artiva headquartered?

Artiva is headquartered in San Diego, California, United States.

What industry is Artiva in?

Artiva operates in Biotech, Healthcare.

Artiva

IPO

San Diego, United States · Founded 2019 · $198.0M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 51–200
Founded: 2019
Business Model: B2B

Total Funding: $198.0M
Last Round: $120.0M Series BFeb 2021
Rounds: 2

About

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy designed to be produced at scale from donor cells and used in combination with B-cell targeted monoclonal antibodies. Unlike autologous CAR-T therapies, AlloNK is manufactured off-the-shelf, stored frozen, and can be administered in community settings. Artiva's manufacturing-first approach, developed in partnership with GC Cell Corporation, enables production of enough therapy to treat over 1,000 autoimmunity patients annually from its San Diego facility. The company went public on NASDAQ in July 2024.

Summary

Artiva is a Biotech company based in San Diego, United States, founded in 2019. It has raised $198.0M in total across 2 rounds, most recently a $120.0M Series B round in Feb 2021. Investors include 5AM Ventures, RA Capital Management and venBIO Partners.